

A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma

Pratt, Guy; Yap, Christina; Oldreive, Ceri; Slade, Daniel; Bishop, Rebecca; Griffiths, Mike; Dyer, Martin J S; Fegan, Chris; Oscier, David; Pettitt, Andrew; Matutes, Estella; Devereux, Stephen; Allsup, David; Bloor, Adrian; Hillmen, Peter; Follows, George; Rule, Simon; Moss, Paul; Stankovic, Tatjana

DOI:

[10.1111/bjh.14793](https://doi.org/10.1111/bjh.14793)

License:

Other (please specify with Rights Statement)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Pratt, G, Yap, C, Oldreive, C, Slade, D, Bishop, R, Griffiths, M, Dyer, MJS, Fegan, C, Oscier, D, Pettitt, A, Matutes, E, Devereux, S, Allsup, D, Bloor, A, Hillmen, P, Follows, G, Rule, S, Moss, P & Stankovic, T 2018, 'A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma', *British Journal of Haematology*, vol. 182, no. 3, pp. 429-433. <https://doi.org/10.1111/bjh.14793>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

This is the peer reviewed version of the following article: Pratt, G., Yap, C., Oldreive, C., Slade, D., Bishop, R., Griffiths, M., Dyer, M. J. S., Fegan, C., Oscier, D., Pettitt, A., Matutes, E., Devereux, S., Allsup, D., Bloor, A., Hillmen, P., Follows, G., Rule, S., Moss, P. and Stankovic, T. (2017), A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. *Br J Haematol*. doi:10.1111/bjh.14793, which has been published in final form at 10.1111/bjh.14793. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 04. May. 2023

Table II: Adverse Events: All grades and grade ≥ 3

Event	Capsule (n=9)			Tablet(n=6)			Total (n=15)	
	200mg bd (n=6)		400mg bd (n=3)	100mg bd (n=6)		Overall		
	All Grades	≥ 3	All Grades	All Grades	≥ 3	All Grades	All Grades	≥ 3
Abdominal pain	1	0	0	1	0	2	2	0
Acute kidney injury	0	0	0	1	1	1	1	1
Alkaline phosphatase increased	0	0	0	1	0	1	1	0
Alopecia	0	0	0	1	0	1	1	0
Anemia	4	1	2	4	2	10	10	5
Anorexia	1	0	0	1	0	2	2	0
Back pain	2	0	0	0	0	2	2	0
Blood and lymphatic system disorders - Other, specify	0	0	1	1	0	2	2	0
Blood bilirubin increased	1	0	0	1	0	2	2	0
Bruising	0	0	0	1	0	1	1	0
Bullous dermatitis	0	0	0	1	0	1	1	0
Buttock pain	0	0	0	1	0	1	1	0
Cardiac disorders - Other, specify	0	0	1	0	0	1	1	1
Conjunctivitis	0	0	1	0	0	1	1	0
Cough	1	0	0	2	0	3	3	0
Creatinine increased	2	0	0	0	0	2	2	0
Diarrhea	1	0	1	2	0	4	4	1
Dizziness	1	0	0	1	0	2	2	0
Dyspepsia	0	0	1	1	0	2	2	0
Dyspnea	1	0	1	2	0	4	4	1
Ear and labyrinth disorders - Other, specify	1	0	0	0	0	1	1	0
Edema face	0	0	0	1	0	1	1	0
Edema limbs	0	0	0	1	1	1	1	1
Epistaxis	1	0	0	1	0	2	2	0
Eye infection	0	0	0	1	0	1	1	0
Fatigue	3	0	1	4	1	8	8	2
Febrile neutropenia	1	1	0	0	0	1	1	1
Flatulence	0	0	0	1	0	1	1	0
Flu like symptoms	1	0	0	0	0	1	1	0
General disorders and administration site conditions - Other, specify	1	0	0	1	0	2	2	0
Generalized muscle weakness	0	0	0	1	0	1	1	0
Hematoma	1	0	0	0	0	1	1	0
Hypercalcemia	0	0	0	1	0	1	1	0
Hyperglycemia	0	0	0	1	0	1	1	0
Hypoalbuminemia	1	0	0	3	0	4	4	0
Hypocalcemia	2	0	0	2	0	4	4	0
Hyponatremia	1	0	0	1	0	2	2	0
Hypotension	1	0	0	0	0	1	1	0
INR increased	0	0	0	1	0	1	1	1
Laryngeal hemorrhage	0	0	1	0	1	1	1	1

Laryngeal inflammation	1	0	0	0	0	0	0	0	1	0
Localized edema	0	0	0	0	0	0	0	0	1	0
Lung infection	1	0	0	0	0	0	0	0	1	0
Lymphocyte count decreased	0	0	0	0	0	0	0	0	1	1
Lymphocyte count increased	0	0	0	0	0	0	0	0	1	0
Nasal congestion	1	0	0	0	0	0	0	0	1	0
Nausea	1	0	0	2	1	0	0	0	5	1
Neck edema	0	0	0	0	0	0	0	0	1	0
Neuralgia	0	0	0	0	0	0	0	0	1	0
Neutrophil count decreased	2	1	1	1	1	2	1	0	5	3
Oral hemorrhage	1	0	0	0	0	0	0	0	1	0
Other, specify	1	0	0	1	0	0	0	0	4	1
Pain in extremity	0	0	0	0	0	0	0	0	1	0
Papulopustular rash	0	0	0	0	0	0	0	0	1	1
Platelet count decreased	4	3	2	2	1	1	1	1	8	5
Pleuritic pain	0	0	1	1	1	0	0	0	1	1
Pruritus	0	0	0	0	0	0	0	0	1	0
Rash maculo-papular	0	0	1	1	1	1	0	0	2	1
Rhinitis infective	1	0	0	0	0	0	0	0	1	0
Serum amylase increased	1	0	0	0	0	0	0	0	1	0
Sinus tachycardia	0	0	0	0	0	0	0	0	1	0
Skin and subcutaneous tissue disorders - Other, specify	0	0	0	0	0	0	0	2	2	1
Upper respiratory infection	0	0	1	1	1	1	0	0	2	1
Ventricular tachycardia	0	0	0	0	0	0	0	0	1	0
Vomiting	2	0	0	0	0	0	0	0	2	0
Weight loss	0	0	0	0	0	0	0	0	1	0
White blood cell decreased	0	0	0	0	0	0	0	0	1	0
All Events	6	3	3	3	3	6	4	15	10	